Safety and Efficacy of RHH646 for Knee Osteoarthritis
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 82
- Registration Number
- NCT05816395
- Locations
- 🇺🇸
Clinical Trials Research, Lincoln, California, United States
🇺🇸Conquest Research, Winter Park, Florida, United States
🇺🇸Clinical Trial Network ., Houston, Texas, United States
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT05816720
- Locations
- 🇺🇸
Excel Diagnostics & Nuclear Oncology Center, Houston, Texas, United States
Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)
- Conditions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT05815212
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 174
- Registration Number
- NCT05809986
- Locations
- 🇵🇹
Novartis Investigative Site, Lisboa, Portugal
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05809895
Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients
- Conditions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 214
- Registration Number
- NCT05806268
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 700
- Registration Number
- NCT05803941
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸St. Joseph Hospital ., Orange, California, United States
🇺🇸Providence Saint Johns Health Ctr ., Santa Monica, California, United States
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT05798117
- Locations
- 🇺🇸
Division of Rheumatology Immunology, Birmingham, Alabama, United States
🇺🇸WA Uni School Of Med WUSCM, Saint Louis, Missouri, United States
🇨🇭Novartis Investigative Site, Lausanne, Switzerland
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT05795140
- Locations
- 🇮🇳
Novartis Investigative Site, Nagpur, Maharashtra, India
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 144
- Registration Number
- NCT05795153
- Locations
- 🇺🇸
Treasure Valley Medical Research, Boise, Idaho, United States
🇺🇸Allergy and Clinical Immunology Ass, Pittsburgh, Pennsylvania, United States
🇺🇸Florida Ctr Allergy Asthma Research ., Aventura, Florida, United States